Therefore, the CasRx-mediated knockdown of Ripk1 and Nsf holds promise for future therapeutic applications aimed at ameliorating cerebral lesions and neurological deficits following ischemic stroke. This evidence concerns the gene RIPK1 and ischemic stroke.